Proteomics and polycystic ovary syndrome

References

• Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J. Clin. Endocrinol. Metab. 84(6), 1897–1899 (1999).
   PubMed Web of Science ®Google Scholar
• Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 85(7), 2434–2438 (2000).
   PubMed Web of Science ®Google Scholar
• Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89(6), 2745–2749 (2004).
   PubMed Web of Science ®Google Scholar
• Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecol. Obstet. Invest. 69(4), 274–280 (2010).
   PubMedGoogle Scholar
• Azziz R, Carmina E, Dewailly Det al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 91(11), 4237–4245 (2006).
   PubMed Web of Science ®Google Scholar
• Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int. J. Obes. Relat. Metab. Disord. 26(7), 883–896 (2002).
   PubMed Web of Science ®Google Scholar
• Carmina E, Bucchieri S, Esposito Aet al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J. Clin. Endocrinol. Metab. 92(7), 2500–2505 (2007).
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol. Metab. 18(7), 266–272 (2007).
   PubMed Web of Science ®Google Scholar
• Borruel S, Fernandez-Duran E, Alpañes Met al. Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J. Clin. Endocrinol. Metab. 98(3), 1254–1263 (2013).
   PubMed Web of Science ®Google Scholar
• Wickenheisser JK, Nelson-DeGrave VL, McAllister JM. Human ovarian theca cells in culture. Trends Endocrinol. Metab. 17(2), 65–71 (2006).
   PubMed Web of Science ®Google Scholar
• DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril. 83(5), 1454–1460 (2005).
   PubMed Web of Science ®Google Scholar
• Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J. Clin. Endocrinol. Metab. 90(8), 4650–4658 (2005).
   PubMed Web of Science ®Google Scholar
• Garcia-Romero G, Escobar-Morreale HF. Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus. Curr. Diab. Rev. 2(1), 39–49 (2006).
   PubMedGoogle Scholar
• Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch. Intern. Med. 166(19), 2081–2086 (2006).
   PubMedGoogle Scholar
• Wild RA, Carmina E, Diamanti-Kandarakis Eet al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95(5), 2038–2049 (2010).
   PubMed Web of Science ®Google Scholar
• Kosova G, Urbanek M. Genetics of the polycystic ovary syndrome. Mol. Cell. Endocrinol. 373(1–2), 29–38 (2013).
   PubMedGoogle Scholar
• Zawadzki JKDA. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Polycystic ovary Syndrome. Dunaif A, Givens JR, Haseltine FP, Merriam GR (Eds). Blackwell Scientific Publications, Boston, MA, USA, 377–384 (1992).
   Google Scholar
• The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19(1), 41–47 (2004).
   Google Scholar
• Mischak H, Apweiler R, Banks REet al. Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin. Appl. 1(2), 148–156 (2007).
   PubMed Web of Science ®Google Scholar
• Tuck MK, Chan DW, Chia Det al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J. Proteome Res. 8(1), 113–117 (2009).
   PubMed Web of Science ®Google Scholar
• Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics. 1(11), 845–867 (2002).
   PubMed Web of Science ®Google Scholar
• Darde VM, Barderas MG, Vivanco F. Depletion of high-abundance proteins in plasma by immunoaffinity subtraction for two-dimensional difference gel electrophoresis analysis. Methods Mol. Biol. 357, 351–364 (2007).
   PubMedGoogle Scholar
• Elliott MH, Smith DS, Parker CE, Borchers C. Current trends in quantitative proteomics. J. Mass Spectrom. 44(12), 1637–1660 (2009).
   PubMed Web of Science ®Google Scholar
• Wu WW, Wang G, Baek SJ, Shen RF. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J. Proteome Res. 5(3), 651–658 (2006).
   PubMed Web of Science ®Google Scholar
• Malik R, Dulla K, Nigg EA, Korner R. From proteome lists to biological impact--tools and strategies for the analysis of large MS data sets. Proteomics 10(6), 1270–1283 (2010).
   PubMed Web of Science ®Google Scholar
• Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum. Reprod. Update 19(3), 268–288 (2013).
   PubMed Web of Science ®Google Scholar
• Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89(6), 2548–2556 (2004).
   PubMed Web of Science ®Google Scholar
• Fruhbeck G. Overview of adipose tissue and its role in obesity and metabolic disorders. Methods Mol. Biol. 456, 1–22 (2008).
   PubMedGoogle Scholar
• Peinado JR, Pardo M, de la Rosa O, Malagon MM. Proteomic characterization of adipose tissue constituents, a necessary step for understanding adipose tissue complexity. Proteomics 12(4–5), 607–620 (2012).
   PubMed Web of Science ®Google Scholar
• Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol. Sci. 24(6), 276–283 (2003).
   PubMedGoogle Scholar
• Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes. Rev. 11(1), 11–18 (2010).
   PubMed Web of Science ®Google Scholar
• Fox CS, Massaro JM, Hoffmann Uet al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116(1), 39–48 (2007).
   PubMed Web of Science ®Google Scholar
• Goodpaster BH, Krishnaswami S, Harris TBet al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch. Intern. Med. 165(7), 777–783 (2005).
   PubMed Web of Science ®Google Scholar
• Pascot A, Lemieux S, Lemieux Iet al. Age-related increase in visceral adipose tissue and body fat and the metabolic risk profile of premenopausal women. Diabetes Care 22(9), 1471–1478 (1999).
   PubMed Web of Science ®Google Scholar
• Corton M, Villuendas G, Botella JI, San Millan JL, Escobar-Morreale HF, Peral B. Improved resolution of the human adipose tissue proteome at alkaline and wide range pH by the addition of hydroxyethyl disulfide. Proteomics 4(2), 438–441 (2004).
   PubMedGoogle Scholar
• Insenser M, Montes-Nieto R, Vilarrasa Net al. A nontargeted proteomic approach to the study of visceral and subcutaneous adipose tissue in human obesity. Mol. Cell. Endocrinol. 363(1–2), 10–19 (2012).
   PubMed Web of Science ®Google Scholar
• Ahmed M, Neville MJ, Edelmann MJ, Kessler BM, Karpe F. Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity (Silver Spring) 18(1), 27–34 (2009).
   PubMedGoogle Scholar
• Salgado-Somoza A, Teijeira-Fernandez E, Fernandez AL, Gonzalez-Juanatey JR, Eiras S. Proteomic analysis of epicardial and subcutaneous adipose tissue reveals differences in proteins involved in oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 299(1), H202–H209 (2010).
   Google Scholar
• Roca-Rivada A, Alonso J, Al-Massadi Oet al. Secretome analysis of rat adipose tissues shows location-specific roles for each depot type. J. Proteomics 74(7), 1068–1079 (2011).
   PubMedGoogle Scholar
• Celis JE, Moreira JM, Cabezon Tet al. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol. Cell. Proteomics 4(4), 492–522 (2005).
   PubMed Web of Science ®Google Scholar
• Rajesh RV, Heo GN, Park MRet al. Proteomic analysis of bovine omental, subcutaneous and intramuscular preadipocytes during in vitro adipogenic differentiation. Comp. Biochem. Physiol. Part D Genomics Proteomics 5(3), 234–244 (2010).
   PubMedGoogle Scholar
• Ma X, Fan L, Meng Yet al. Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome. Mol. Hum. Reprod. 13(8), 527–535 (2007).
   PubMed Web of Science ®Google Scholar
• Choi DH, Lee WS, Won Met al. The apolipoprotein A-I level is downregulated in the granulosa cells of patients with polycystic ovary syndrome and affects steroidogenesis. J. Proteome Res. 9(9), 4329–4336 (2010).
   PubMedGoogle Scholar
• Kim YS, Gu BH, Choi BCet al. Apolipoprotein A-IV as a novel gene associated with polycystic ovary syndrome. Int. J. Mol. Med. 31(3), 707–716 (2013).
   PubMed Web of Science ®Google Scholar
• Dai G, Lu G. Different protein expression patterns associated with polycystic ovary syndrome in human follicular fluid during controlled ovarian hyperstimulation. Reprod. Fertil. Dev. 24(7), 893–904 (2012).
   PubMedGoogle Scholar
• Adams J, Franks S, Polson DWet al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 2(8469–70), 1375–1379 (1985).
   PubMedGoogle Scholar
• Franks S, Mason H, Willis D. Follicular dynamics in the polycystic ovary syndrome. Mol. Cell. Endocrinol. 163(1–2), 49–52 (2000).
   PubMed Web of Science ®Google Scholar
• Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum. Reprod. Update 14(4), 367–378 (2008).
   PubMed Web of Science ®Google Scholar
• Fortune JE. Ovarian follicular growth and development in mammals. Biol. Reprod. 50(2), 225–232 (1994).
   PubMed Web of Science ®Google Scholar
• Misiti S, Stigliano A, Borro Met al. Proteomic profiles in hyperandrogenic syndromes. J. En.docrinol. Invest. 33(3), 156–164 (2010).
   PubMedGoogle Scholar
• Borro M, Gentile G, Stigliano A, Misiti S, Toscano V, Simmaco M. Proteomic analysis of peripheral T lymphocytes, suitable circulating biosensors of strictly related diseases. Clin. Exp. Immunol. 150(3), 494–501 (2007).
   PubMedGoogle Scholar
• Coombs KM. Quantitative proteomics of complex mixtures. Expert Rev. Proteomics 8(5), 659–677 (2011).
   PubMed Web of Science ®Google Scholar
• Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18(11), 2071–2077 (1997).
   PubMed Web of Science ®Google Scholar
• Corton M, Botella-Carretero JI, Lopez JAet al. Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry. Hum. Reprod. 23(3), 651–661 (2008).
   PubMedGoogle Scholar
• Insenser M, Martinez-Garcia MA, Montes R, San-Millan JL, Escobar-Morreale HF. Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation. J. Clin. Endocrinol. Metab. 95(8), 3863–3870 (2010 ).
   PubMedGoogle Scholar
• Montes-Nieto R, Insenser M, Martinez-Garcia MA, Escobar-Morreale HF. A nontargeted proteomic study of the influence of androgen excess on human visceral and subcutaneous adipose tissue proteomes. J. Clin. Endocrinol. Metab. 98(3), E576–E585 (2013).
   Google Scholar
• Matharoo-Ball B, Hughes C, Lancashire Let al. Characterization of Biomarkers in Polycystic Ovary Syndrome (PCOS) using multiple distinct proteomic platforms. J. Proteome Res. 6(8), 3321–3328 (2007).
   PubMed Web of Science ®Google Scholar
• Zhao S, Qiao J, Li M, Zhang X, Yu J, Li R. Discovery of distinct protein profiles for polycystic ovary syndrome with and without insulin resistance by surface-enhanced laser adsorption/ionization time of flight mass spectrometry. Fertil. Steril. 88(1), 145–151 (2007).
   PubMedGoogle Scholar
• Insenser M, Montes-Nieto R, Murri M, Escobar-Morreale HF. Proteomic and metabolomic approaches to the study of polycystic ovary syndrome. Mol. Cell. Endocrinol. 370(1–2), 65–77 (2013).
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF. Iron metabolism and the polycystic ovary syndrome. Trends Endocrinol. Metab. 23(10), 509–515 (2012).
   PubMed Web of Science ®Google Scholar
• Shah PK. Atherosclerosis: targeting endogenous apo A-I--a new approach for raising HDL. Nat. Rev. Cardiol. 8(4), 187–188 (2011).
   PubMedGoogle Scholar
• Corton M, Botella-Carretero JI, Benguria Aet al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92(1), 328–337 (2007).
   PubMedGoogle Scholar
• Valkenburg O, Steegers-Theunissen RP, Smedts HPet al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J. Clin. Endocrinol. Metab. 93(2), 470–476 (2008).
   PubMed Web of Science ®Google Scholar
• Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin. Endocrinol. (Oxf.) 41(4), 463–471 (1994).
   PubMed Web of Science ®Google Scholar
• Legro RS, Blanche P, Krauss RM, Lobo RA. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertil. Steril. 72(6), 990–995 (1999).
   PubMedGoogle Scholar
• Yang F, Linehan LA, Friedrichs WE, Lalley PA, Sakaguchi AY, Bowman BH. Characterization of the mouse haptoglobin gene. Genomics 18(2), 374–380 (1993).
   PubMedGoogle Scholar
• Alvarez-Blasco F, Martinez-Garcia MA, Luque-Ramirez M, Parraza N, San Millan JL, Escobar-Morreale HF. Role of haptoglobin in polycystic ovary syndrome (PCOS), obesity and disorders of glucose tolerance in premenopausal women. PLoS ONE 4(5), e5606 (2009).
   Google Scholar
• Karakurt F, Gumus, II, Bavbek Net al. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. Gynecol. Endocrinol. 24(9), 491–497 (2008).
   PubMed Web of Science ®Google Scholar
• Manneras-Holm L, Baghaei F, Holm Get al. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 96(4), 1068–1076 (2011).
   PubMedGoogle Scholar
• Gonzalez F, Kirwan JP, Rote NS, Minium J. Elevated circulating levels of tissue factor in polycystic ovary syndrome. Clin. Appl. Thromb. Hemost. 19(1), 66–72 (2012).
   PubMedGoogle Scholar
• Lindholm A, Bixo M, Eliasson Met al. Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. Gynecol. Endocrinol. 26(10), 743–748 (2012).
   Google Scholar
• Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J. Clin. Endocrinol. Metab. 87(8), 3871–3875 (2002).
   PubMed Web of Science ®Google Scholar
• Fan L, Ling J, Ma X, Cui YG, Liu JY. Involvement of HSP10 during the ovarian follicular development of polycystic ovary syndrome: Study in both human ovaries and cultured mouse follicles. Gynecol. Endocrinol. 25(6), 392–397 (2009).
   PubMed Web of Science ®Google Scholar
• Rayner K, Chen YX, Siebert T, O'Brien ER. Heat shock protein 27: clue to understanding estrogen-mediated atheroprotection? Trends Cardiovasc. Med. 20(2), 54–58 (2010).
   PubMedGoogle Scholar
• Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil. Steril. 95(3), 1048–1058 e1041-e1042 (2011).
   PubMed Web of Science ®Google Scholar